Cyteir Therapeutics, Inc.
CYT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $5 | $9 | $7 |
| G&A Expenses | $2 | $4 | $4 | $3 |
| SG&A Expenses | $2 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $5 | $10 | $13 | $10 |
| Operating Income | -$5 | -$10 | -$13 | -$10 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $1 | $1 | $1 |
| Pre-Tax Income | -$4 | -$8 | -$12 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$8 | -$12 | -$7 |
| % Margin | – | – | – | – |
| EPS | -0.098 | -0.24 | -0.32 | -0.21 |
| % Growth | 59.2% | 25% | -52.4% | – |
| EPS Diluted | -0.098 | -0.24 | -0.32 | -0.21 |
| Weighted Avg Shares Out | 36 | 36 | 36 | 35 |
| Weighted Avg Shares Out Dil | 36 | 36 | 36 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$5 | -$9 | -$13 | -$9 |
| % Margin | – | – | – | – |